title: The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials.
abstract: OBJECTIVE
  Mirabegron, a potent and selective β3-adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB). We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug for treating OAB.
  
  
  METHODS
  A literature review was performed to identify all published randomized double-blind, placebo-controlled phase III trials of mirabegron for the treatment of OAB. The search included the following databases: MEDLINE, EMBASE and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. A systematic review and meta-analysis of phase III trials were conducted.
  
  
  RESULTS
  Four publications involving a total of 5,761 patients were used in the analysis, including four phase III RCTs that compared mirabegron with placebo. We found that mirabegron was effective in treating OAB in our meta-analysis. Co-primary efficacy end points: the mean number of incontinence episodes per 24 h (the standardized mean difference (SMD) = -0.44, 95 % confidence interval (CI) -0.59 to -0.29, p < 0.00001); the mean number of micturitions per 24 h (SMD = -0.62, 95 % CI -0.80 to -0.45, p < 0.00001) and key secondary efficacy end points: mean volume voided per micturition; mean number of urgency episodes per 24 h indicated that mirabegron was more effective than the placebo. Safety assessments included common treatment-emergent adverse events (TEAEs) [OR 1.10, 95 % CI 0.93-1.31, p = 0.25), hypertension, cardiac arrhythmia TEAEs, urinary retention and discontinuations due to adverse event indicated that mirabegron was well tolerated.
  
  
  CONCLUSIONS
  This meta-analysis indicates that mirabegron to be an effective and safe treatment for OAB symptoms with a low occurrence of side effects. It offers promise as an effective oral agent for the treatment of OAB with a distinct efficacy/tolerability balance.
authors.affiliation: Department of Urology, Beijing Tian-Tan Hospital, Capital Medical University, No. 6 Tiantan Xi Li, Dongcheng District, Beijing, 100050, China.
authors.forename: Yuanshan
authors.initials: Y
authors.lastname: Cui
authors.forename: Huantao
authors.initials: H
authors.lastname: Zong
authors.forename: Chenchen
authors.initials: C
authors.lastname: Yang
authors.forename: Huilei
authors.initials: H
authors.lastname: Yan
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000083:Acetanilides / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014554:Urination / Q000187:drug effects
chemical_list: D000083:Acetanilides; D018727:Muscarinic Antagonists; D013844:Thiazoles; C520025:mirabegron
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: J Urol. 2013 Apr;189(4):1388-95
references.pmid: 23079373
references.citation: Physiol Rev. 2004 Jul;84(3):935-86
references.pmid: 15269341
references.citation: Expert Opin Pharmacother. 2002 Jul;3(7):827-33
references.pmid: 12083983
references.citation: Eur Urol. 2013 Feb;63(2):283-95
references.pmid: 23182126
references.citation: Neurourol Urodyn. 2002;21(2):167-78
references.pmid: 11857671
references.citation: Eur Urol. 2013 Feb;63(2):296-305
references.pmid: 23195283
references.citation: BJU Int. 2012 Dec;110(11):1767-74
references.pmid: 22409769
references.citation: Eur J Clin Pharmacol. 2011 May;67(5):535-6
references.pmid: 21061118
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: Urology. 2000 May;55(5A Suppl):33-46; discussion 50
references.pmid: 10767450
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):473-81
references.pmid: 18311486
references.citation: Korean J Urol. 2010 Dec;51(12):811-8
references.pmid: 21221199
references.citation: Br J Pharmacol. 2006 Jul;148(5):565-78
references.pmid: 16751797
references.citation: Neurourol Urodyn. 2003;22(4):338-42
references.pmid: 12808710
references.citation: J Pharmacol Exp Ther. 2007 May;321(2):642-7
references.pmid: 17293563
references.citation: Cell Tissue Res. 2010 Nov;342(2):295-306
references.pmid: 20953633
references.citation: Open Access J Urol. 2010 Feb 11;2:11-24
references.pmid: 24198609
references.citation: Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5
references.pmid: 17049716
references.citation: J Manag Care Pharm. 2008 Apr;14(3):291-301
references.pmid: 18439051
references.citation: BJU Int. 2010 May;105(9):1276-82
references.pmid: 19912188
references.citation: J Pharmacol Exp Ther. 1999 Mar;288(3):1367-73
references.pmid: 10027879